A solid-phase approach towards the synthesis of PDE5 inhibitors

被引:13
作者
Beer, D [1 ]
Bhalay, G [1 ]
Dunstan, A [1 ]
Glen, A [1 ]
Haberthuer, S [1 ]
Moser, H [1 ]
机构
[1] Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England
关键词
D O I
10.1016/S0960-894X(02)00296-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PDE5 inhibitors based upon the xanthine scaffold 8 have been expediently synthesized using a solid-phase route. Attachment of the xanthine scaffold 8 using the Rink chloride linker 4 and N-1 functionalization using Mitsunobu chemistry is described. A library of compounds was produced in multi-milligram quantities with excellent purities and acceptable yields. The compounds were tested for their PDE5 inhibitory activity. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1973 / 1976
页数:4
相关论文
共 12 条
[1]  
BEAVO JA, 1970, MOL PHARMACOL, V6, P597
[2]   Pharmacotherapy for erectile dysfunction [J].
Bivalacque, TJ ;
Champion, HC ;
Hellstrom, WJG ;
Kadowitz, PJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (12) :484-489
[3]   IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61
[4]   Reagents for combinatorial organic synthesis: Preparation and uses of rink-chloride [J].
Garigipati, RS .
TETRAHEDRON LETTERS, 1997, 38 (39) :6807-6810
[5]   Sildenafil (Viagra) and ophthalmology [J].
Marmor, MF ;
Kessler, R .
SURVEY OF OPHTHALMOLOGY, 1999, 44 (02) :153-162
[6]  
Maw GN, 1999, ANNU REP MED CHEM, V34, P71
[7]   STRUCTURE-ACTIVITY-RELATIONSHIPS IN A SERIES OF XANTHINE DERIVATIVES WITH ANTIBRONCHOCONSTRICTORY AND BRONCHODILATORY ACTIVITIES [J].
MERLOS, M ;
GOMEZ, L ;
VERICAT, ML ;
BARTROLI, J ;
GARCIARAFANELL, J ;
FORN, J .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1990, 25 (08) :653-658
[8]   THE USE OF DIETHYL AZODICARBOXYLATE AND TRIPHENYLPHOSPHINE IN SYNTHESIS AND TRANSFORMATION OF NATURAL-PRODUCTS [J].
MITSUNOBU, O .
SYNTHESIS-STUTTGART, 1981, (01) :1-28
[9]  
Osterloh IH, 1999, INT J CLIN PRACT, P3
[10]   Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility [J].
Rotella, DP .
DRUGS OF THE FUTURE, 2001, 26 (02) :153-162